Clinical Trial

Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?

Study acronym: rFSH and hMG
Recruiting
View on ClinicalTrials.gov →
Summary
Gonal-F® (follitropin alfa) is a recombinant FSH without LH activity, while Menopur® contains both LH and hCG. The MEGASET trial compared Menopur® and Gonal-F® in GnRH antagonist cycles with SET, showing similar efficacy. A subsequent study (MEGASET-HR) in high responders found ongoing pregnancy rates of 35.5% for Menopur® and 30.7% for Gonal-F®, with a lower early pregnancy loss for Menopur® (14.5% vs 25.5%). Telomere length (TL) in oocyte cumulus cells (CC) correlates with oocyte quality and embryo outcomes. This study aims to assess whether stimulation type (hMG vs. Gonal-F) affects TL in CC and subsequent blastocyst development. A randomized, open-label, cross-over study in normo-responders will analyze telomere length, embryo quality, and hormonal markers.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-12-10; most recent amendment 2025-07-24.
Status change: Not Yet Recruiting → Recruiting 2025-07-24
Trial Details
NCT Number NCT06732843
Lead Sponsor ART Fertility Clinics LLC
Collaborators: Merck Sharp & Dohme LLC
Conditions OVARIAN STIMULATION, Telomere Length, Telomere Length, Mean Leukocyte
Enrollment 10 participants
Start Date 2025-07-23
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-25